RxDoctor Payments Data

Kimberly Kwei, MD

Neurology · New York, NYNPI 1477971661

Payments from drug & device makers

$674,470in general payments, 2019–2025

Across 52 payments — averaging $12,971 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche TCRC, Inc.$547K
  • Regeneron$122K
  • Genentech, Inc.$3K
  • Medtronic$486
  • Boston Scientific$429
  • Abbott$184
  • plus $344 from 4 others

What the payments were for

  • Food & beverage$1,443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Roche TCRC, Inc.29$547,119
Regeneron2$122,465
Genentech, Inc.2$3,443
Medtronic3$486
Boston Scientific5$429
Abbott2$184
AbbVie(2 entities)6$146
Insightec,inc1$146
Teva Pharmaceuticals USA, Inc.1$27
Biogen1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$674,470 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$102,515
Medicare patients
209
Services billed
3,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate25$123,571
RytaryCarbidopa/Levodopa22$31,123
Rivastigmine54$12,190
Carbidopa-LevodopaCarbidopa/Levodopa196$9,882
Carbidopa-Levodopa ErCarbidopa/Levodopa67$8,254
Gabapentin60$2,350
Selegiline Hcl14$2,097
Mirtazapine40$2,061
AmantadineAmantadine Hcl16$1,480
RivastigmineRivastigmine Tartrate21$1,336
Escitalopram Oxalate56$1,320
Midodrine Hcl11$1,192
Clonazepam39$611
Baclofen27$572
Primidone18$477

Paid to pharmacies, not to this prescriber.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →